Navigation
banner
Together we Drive the Future

Inflammatory & Immunological Biomarkers

2017-02-212017-02-212017-01-26
EARLY BIRD DISCOUNT! Register by Feb 21, 2017 to receive 10% off your registration!
Or register 3 for the price of 2 with the coupon code rcdvb!


KEYNOTE SPEAKERS

Kenneth Emancipator
Executive Medical Director and Head of Companion Diagnostics
Merck & Co.
Kenneth Emancipator
Executive Medical Director and Head of Companion Diagnostics
Merck & Co.
 
About Speaker:

Kenneth Emancipator, MD, DABP is a nationally renowned pathologist who is the Executive Medical Director and Head of Companion Diagnostics for Merck & Company. He led the Merck team which partnered with Dako North America to develop the PD-L1 test, which identifies those non-small cell lung cancer patients most likely to benefit from Keytruda® (pembrolizumab), and which is the first companion diagnostic in cancer immunotherapy to be approved by the US Food and Drug Administration. The PD-L1 test enabled Keytruda to become the first immunotherapy to be approved for first-line treatment of non-small cell lung cancer. Dr. Emancipator was one of six members of the Keytruda Team to receive the 2015 PhRMA Research and Hope Award for Biopharmaceutical Industry Research on behalf of Merck.

Dr. Emancipator’s primary interest has always been the role of diagnostic tests in driving clinical decisions. His current focus is personalized medicine, with a special emphasis on precision immuno-oncology. He has in-depth experience with in vitro diagnostics from every perspective, having served as medical director both for academic clinical laboratories and for diagnostics manufacturers, and having been a reviewer for the US Food and Drug Administration, before joining the pharmaceutical industry.

Dr. Emancipator received his A.B. degree from Harvard University and his MD from St. Louis University. He completed his medical internship at Westchester County Medical Center and his pathology residency at the State University of New York at Stony Brook. He has held appointments at the US National Institutes of Health, the US Food and Drug Administration, Cornell University, Beth Israel Medical Center, Bayer Healthcare, Siemens Healthcare, and Abbott Molecular prior to joining Merck. He also has held various leadership positions with the American Society for Clinical Pathology (ASCP), including chairing its Council on Clinical Chemistry, serving on its Board of Certification, serving on its Finance Committee, and eventually being elected Treasurer and to the Board of Directors. He continues to serve as a reviewer for ASCP’s American Journal of Clinical Pathology.

Dr. Emancipator has authored over 100 publications and has presented at more than 100 extramural programs. When not in his office at Merck, he is most likely to be found along the beaches and coastal waterways of Eastern Long Island.

DISTINGUISHED SPEAKERS

Frédéric Baribaud
Associate Scientific Director
Janssen
Frédéric Baribaud
Associate Scientific Director
Janssen
 
About Speaker:

Fred is an Associate Director in the Systems Pharmacology & Biomarkers department at Janssen R&D which he joined in 2006. He has been working in various inflammatory diseases working on patient stratification to enable individualized therapeutic treatments.
Fred holds a BS and a MS in Biochemistry from the University of Geneva, Geneva, Switzerland and a PhD in Biology from the University of Lausanne, Lausanne, Switzerland. Fred is a former UPENN postdoctoral fellow where he worked on HIV entry and a former employee of Incyte Inc, were he worked on target validation and was a discovery compound team co-lead for SMI development.


David Choy
Principal Scientific Researcher
Genentech
David Choy
Principal Scientific Researcher
Genentech
 
About Speaker:

David Choy is a principal scientific researcher in the department of Biomarker Discovery OMNI at Genentech where he is responsible for biomarker discovery and research strategy for asthma. With a passion for computational, human genetics, and translational biology approaches, his work has contributed to the discovery of periostin, a biomarker of Type 2 asthma.


Yang Dai
Assistant Professor, Immunology & Microbial Science
The Scripps Research Institute
Yang Dai
Assistant Professor, Immunology & Microbial Science
The Scripps Research Institute
 
About Speaker:

2002, received a Ph.D. degree in Immunology from Memorial University of Newfoundland, St John’s, Canada. 2002-2008, postdoctoral fellow in Dr. Eli Sercarz’s lab in Torrey Pines Institute for Molecular Studies, training in immune regulation and T-cell-mediated autoimmune disease. 2008, started independent research career, and studied secreted microvesicles or exosomes in triggering autoimmune responses and type 1 diabetes in non-obese diabetic mice. His lab found that exosomes are potent immunogen and carry unique autoantigens to stimulate autoreactive B and T cells. The findings have been published in Journal of Immunology, European Journal of Immunology and Diabetes. Recent progress in studying candidate autoantigens expressed in the exosomes demonstrated that endogenous retrovirus antigens are enriched in the exosomes and contribute to the autoimmune responses to pancreatic islets.


Justine Debelius
Postdoctoral Scholar
University of California San Diego
Justine Debelius
Postdoctoral Scholar
University of California San Diego
 
About Speaker:

Justine Debelius is a postdoctoral researcher in the Knight Lab at the University of California, San Diego. Her work focuses on the role of the gut microbiome in the development and management of chronic diseases, especially autoimmune diseases. Dr Debelius received her PhD in 2015 from the University of Colorado, Boulder, where her dissertation focused on the influence of lifestyle factors on the gut microbiome.


Ulrich Hoffmueller
Founder & Chief Business Officer
Epiontis GmbH
Ulrich Hoffmueller
Founder & Chief Business Officer
Epiontis GmbH
 
About Speaker:

Since the foundation of Epiontis in 2003, in which Uli participated as a founder, he is Chief Business Officer of the company. Prior to founding Epiontis, he worked at Jerini AG, Berlin, Germany (now part of Shire Pharmaceuticals) from 1999 to 2003 as Director of Business Development. Uli completed business school in Berlin, Germany and Cambridge, UK from 2002 to 2004 in parallel to his positions in the biotech industry. He earned his Ph.D. at the Charité University Clinic, Berlin, Germany, in 1998, and was honored with the Charité Research Award in 1997. Uli received his Diplom (Masters) in Biochemistry in 1995 from Humboldt University, Berlin, Germany.


Yinling Hu
Ph.D., Senior Investigator
National Cancer Institute
Yinling Hu
Ph.D., Senior Investigator
National Cancer Institute
 
About Speaker:

Yinling Hu is a senior investigation, head of Inflammation Tumorigenesis section, at the Cancer and Inflammation Program, Center for cancer Research, in the National Cancer Institute, NIH. Currently, Hu’s lab is study the role of IKKalpha in skin, lung and esophageal carcinogenesis. Dr. Hu obtained her Ph.D at the University of Melbourne in Australia. She was trained as a postdoc at Michael Karin’s lab of the UCSD in La Jolla California.


Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
 
About Speaker:

1978 MD, 1983 PhD from The University of Tokyo
1984-88 Postdoc at the NCI/NIH
1990 Assistant Professor, La Jolla Institute for Allergy and Immunology (LJI)
2000 Professor, LJI


Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
 
About Speaker:

Stephen Pennington
Professor of Proteomics
University College Dublin
Stephen Pennington
Professor of Proteomics
University College Dublin
 
About Speaker:

Steve graduated from Imperial College of Science and Technology, University of London with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge. During his PhD he was awarded an Elmore Medical Research Fellowship and it was during this fellowship that his interests in the regulation of the mammalian cell cycle began. He was Wellcome Lecturer in the University of Liverpool before moving to Dublin where he is currently Professor of Proteomics in UCD. His research team use a range of proteomics platforms to explore disesase mechanisms and identify biomarkers in oncology and inflammatory disease. Stephen has been awarded a Beit Memorial Fellowship and received a Sir Henry Wellcome Commemorative Award for Innovative Research. He serves on the editorial boards of several journals, and is currenty vice-president of the British Society for Proteome Research, a general council member of the European Proteomics Association and lead organizer of the forthcoming annual congress of the Human Proteome Organisation - HUPO2017 (www.hupo2017.ie).


Geert Schmid-Schonbein
Distinguished Professor and Chairman, Department of Bioengineering
University of California, San Diego
Geert Schmid-Schonbein
Distinguished Professor and Chairman, Department of Bioengineering
University of California, San Diego
 
About Speaker:

Geert W. Schmid-Schönbein is Distinguished Professor and Chairman of the Department of Bioengineering at the University of California San Diego.  He teaches bioengineering of living tissues and cell and molecular mechanics in heath and disease. His research interest is in molecular/cell mechanics and bioengineering analysis of the microcirculation in disease. His group discovered a fundamental mechanism for cell dysfunctions and inflammation due to “Auto-digestion”.

He is Founding Member of AIMBE, former President of the Biomedical Engineering Society, the Microcirculatory Society and the North American Society of Biorheology, Fellow of the American Heart Association, the Biomedical Engineering Society, the Physiological Society, and the International Federation for Medical and Biological Engineering. He is Past Chair of the World Council for Biomechanics and Member of the US National Academy of Engineering. 

 

 

 

 


Martin Schwickart
Scientist II
MedImmune
Martin Schwickart
Scientist II
MedImmune
 
About Speaker:

Martin Schwickart, Ph.D. is currently Scientist II in the Department of Clinical Immunology and Bioanalysis at Medimmune in Mountain View, California. Martin leads assay development and data analysis of cellular and soluble biomarkers. He also develops bioanalytical plans including PK, ADA and Nab support. Martin performed his post-doctoral studies at Genentech and his doctoral studies at the Max-Planck Institute of Molecular Cell Biology and Genetics.


Tracy Staton
Scientist, OMNI Biomarker Development
Genentech
Tracy Staton
Scientist, OMNI Biomarker Development
Genentech
 
About Speaker:

Tracy completed her graduate studies in the Immunology Program at Stanford University School of Medicine, where she worked in the laboratory of Dr. Eugene Butcher to characterize molecular mechanisms of lymphocyte homing. She then did her postdoctoral training at Harvard University School of Public Health in the laboratory of Dr. Laurie Glimcher. During that time, she studied immune cell development and the importance of effector lymphocyte populations in preclinical models of disease. Tracy came to Genentech in 2011 and holds the position of Scientist in the Biomarker Development group. Her interests are in understanding the mechanisms of action of novel therapeutics in human diseases, and using translational pharmacology to improve the effectiveness of clinical development. At Genentech, she has been involved in developing diagnostic and pharmacodynamic biomarker strategies and assays for programs in asthma.

GENERAL PLENARY SPEAKERS

Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
 
About Speaker:

Dr. Bruce W.M. Jordan, Ph.D, FIBMS
VP, International Business Leader – Personalised Healthcare Solutions

Bruce joined the Roche Pharmaceuticals Herceptin team in Basel in 2005, leading the global HER2 Testing/Companion Diagnostics (CDx) activities. Since January 2013 he is VP - International Business Leader – Personalised Healthcare Solutions at Roche Diagnostics – Centralised and Pont of Care Solutions at their HQ in Rotkreuz, Switzerland.

He has worked on CDx development & commercialization out of both the Pharmaceuticals and Diagnostics Divisions over the past 11 years at Roche, across therapeutic areas such as Neurology, Immunology, Fertility and Oncology.

Bruce trained in Laboratory Medicine, graduating from the University of Portsmouth U.K. in 1994 with a BSc. (Hons.) Biomedical Sciences, subsequently gaining State Registration in Haematology and Transfusion Medicine at Southampton General Hospital. He has also worked at the Royal Marsden Hospital, London, and has a Ph.D. in cancer research from the University of Würzburg in Germany.

Bruce has also represented the diagnostics industry as a Corporate Representative at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and is a Fellow of the Institute of Biomedical Sciences (FIBMS) in the U.K., and a member of the European Society of Pharmacogenomics and Personalised Therapy (ESPT)


Stephen Albert Johnston
Director, Center for Innovations in Medicine; Professor, School of Life Sciences, Arizona State University
CEO, Calviri, Inc
Stephen Albert Johnston
Director, Center for Innovations in Medicine; Professor, School of Life Sciences, Arizona State University
CEO, Calviri, Inc
 
About Speaker:

Dr. Johnston directs the Center for Innovations in Medicine (CIM) at the Biodesign Institute. CIM is unique in its focus on inventing disruptive technologies in biomedicine. The mission is to contribute to the transformation of medicine through technologies that allow prevention, early detection and new therapeutic treatment of disease. Toward this goal CIM is focusing on developing three of his inventions. One project is to create a universal, preventative cancer vaccine. A second is to develop a system for continuous, comprehensive, cheap health monitoring. The third is based on an invention for making new therapeutics and targeted anti-infectives.
Johnston largely focuses on invention. He was inventor/ co-inventor of pathogen derived resistance, mitochondrial transformation, TEV protease system, the gene gun, gene immunization, expression library immunization, linear expression elements, synbodies and immunosignaturing. He was professor and director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University before moving to ASU.


Nuno Bandeira
Associate Professor, Computer Science and Engineering; Executive Director, Center for Computational Mass Spectrometry
University of California, San Diego
Nuno Bandeira
Associate Professor, Computer Science and Engineering; Executive Director, Center for Computational Mass Spectrometry
University of California, San Diego
 
About Speaker:

Amos Baruch
Scientist, Development Sciences
Genentech
Amos Baruch
Scientist, Development Sciences
Genentech
 
About Speaker:

Dr. Amos Baruch has over 15 years of combined biomedical experience in Translational Biology, Biochemistry, and Pharmacology. He joined Genentech at the turn of 2011 as a Scientist in the Pharmacodynamic Biomarker (PDB) group.  In his role as a PDB Scientist he develops and executes biomarker strategies for programs in several disease areas including cardiovascular, metabolism, anti-microbial, ophthalmology and wound healing.  Dr. Baruch received his Ph.D. from Tel-Aviv University in 1998. He then relocated to the US to pursue postdoctoral studies at the Scripps Research Institute with Dr. Bernard Gilula and thereafter in the department of Biochemistry and Biophysics at UCSF with Dr. Matthew Bogyo.  Dr. Baruch then Joined Celera Genomics and lead the chemical proteomics group charged with developing small molecule activity based probes to provide pharmacodynamic support for small molecule programs in the areas of Cancer, Asthma and Autoimmune diseases. In 2006, he joined KAI Pharmaceuticals and championed the preclinical research and development of therapeutic peptides for hyperparathyroidism in renal dialysis patients. The lead candidate from that effort was recently approved.   


Catherine Brownstein
Scientific Director, Manton Center for Orphan Disease Research
Boston Children's Hospital
Catherine Brownstein
Scientific Director, Manton Center for Orphan Disease Research
Boston Children's Hospital
 
About Speaker:

Dr. Brownstein is a research associate in Genetics and Genomics, Instructor in Pediatrics, and the manager of the Molecular Genetics Core Facility at Boston Children’s Hospital. Recently named the Scientific Director for the Manton Center for Orphan Disease Research and specializing in gene discovery, Dr. Brownstein has been instrumental in the elucidation of several new disease genes for conditions such as intellectual disability, nemaline myopathy, psychosis, SIDS, and hypophosphatemic rickets. Her current work focuses on advancing the fields of next generation sequencing and analysis, as evidenced in her management of the international CLARITY and CLARITY Undiagnosed competitions.


Melina Cimler
Senior Vice President, Quality & Regulatory
Adaptive Biotech
Melina Cimler
Senior Vice President, Quality & Regulatory
Adaptive Biotech
 
About Speaker:

Melina Cimler is Senior Vice President of Regulatory & Quality at Adaptive Biotechnologies. She has over 27 years of experience in the life science and FDA-regulated diagnostic industry leading regulatory, quality systems, clinical affairs, research, and product development organizations.
Prior to joining Adaptive, Dr. Cimler served as Head of Global Quality and Vice President of Quality, Regulatory, Clinical and Government Affairs at Illumina Inc. She defined and executed on the regulatory strategy resulting in the first next generation sequencing platform (Illumina’s MiSeqDx) receiving FDA marketing authorization.
Previously, she held leadership positions in quality, regulatory and government affairs as Senior Vice President at Beckman Coulter Inc. She also served in senior quality, clinical and regulatory roles at Abbott Molecular, Gen-Probe Inc., and C.R. Bard, and as head of Product Development at Epitope, Inc. (now OraSure Technologies). Dr. Cimler holds a Ph.D. in Pharmacology from the University of Washington.


Peter De Hoff
Research Associate, Reproductive Medicine
University of California San Diego
Peter De Hoff
Research Associate, Reproductive Medicine
University of California San Diego
 
About Speaker:

Research Associate, Sanford Consortium - Placental Dysfunction Biomarker Discovery Program
Scientist II, Synthetic Genomics Inc. - Tools Development in Algal Biofuels Program
Postdoc, Salk Institute for Biological Studies - Evolution of Mating Systems in Green Algae
PhD, UCLA - Gene Discovery in Legume Rhizobium Symbiosis


Anka Ehrhardt
Director Clinical Cytometry
Bristol-Myers Squibb Co.
Anka Ehrhardt
Director Clinical Cytometry
Bristol-Myers Squibb Co.
 
About Speaker:

Dr. Anka Ehrhardt is biophysicist and holds a doctorate in physiology. She is currently working in the United States for Bristol-Myers Squibb.
In her current position at BMS, Dr. Ehrhardt directs the fast growing Clinical Cytometry operation, covering a large portfolio of immuno-oncology, and other disease area clinical studies. Her work focuses on strategies for biomarkers to drive the development of urgently needed new medicines. In this fast-paced environment, Dr. Ehrhardt drives targeted innovation to achieve sustained speed and quality.
Dr. Ehrhardt is currently on the board of different industry organizations, fostering innovation and collaboration between industry, academia and government organizations.


Felix Frueh
Executive Partner
Opus Three LLC
Felix Frueh
Executive Partner
Opus Three LLC
 
About Speaker:

Dr. Felix Frueh is a respected thought leader in personalized medicine with twentyfive years of R&D,
management, and policy experience. He founded Opus Three in 2012 after spending several years at the FDA
and in the payer environment working closely with the pharmaceutical and diagnostic industry.
Dr. Frueh is also Co-Founder and CEO of Intellos Health, a new diagnostic business focused on the development
of affordable tests for the identification of patients requiring confirmatory testing to receive appropriate
therapies.
Prior, he was Chief Scientific Officer at Human Longevity, Inc. and Entrepreneur-in-Residence at Third Rock
Ventures. Dr. Frueh was President of the Medco Research Institute, leading the PBM’s research initiatives in
health economics and outcomes research after having formed Medco’s personalized medicine R&D
organization. Prior to Medco, he was the first Associate Director for Genomics at the FDA, where he oversaw
the development and implementation of policies around biomarker qualification and companion diagnostics.
Dr. Frueh is a Board member at Enterome Biosciences, Ariana Pharmaceuticals, Intellos Health, and
CredibleMeds, and also served on the Board of the Personalized Medicine Coalition. He is a Fellow of the
American College of Clinical Pharmacology and was a faculty member at Georgetown University in
Washington, DC and at the University of North Carolina. Dr. Frueh received his education at Stanford
University and the University of Basel in Switzerland, where he graduated magna cum laude in biochemistry.


Marica Grskovic
Associate Director, R&D
CareDx
Marica Grskovic
Associate Director, R&D
CareDx
 
About Speaker:

Gary Gustavsen
Vice President
Health Advances, LLC
Gary Gustavsen
Vice President
Health Advances, LLC
 
About Speaker:

Gary Gustavsen joined Health Advances in 2005 and leads its Personalized Medicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Prior to joining Health Advances, Gary was a researcher at Brookhaven National Lab evaluating a proprietary line of synthetic growth factors. Gary also worked in the Cell & Tissue Technologies group at Becton Dickinson, the Exploratory Cancer Research group at OSI Pharmaceuticals, and most recently the Corporate Strategy group at Millennium Pharmaceuticals. Gary received his Bachelors degree in Biomedical Engineering from Duke University and his Masters degree in Biomedical Engineering from Stony Brook University.

 

 


Zach Hornby
Chief Operating Officer
Ignyta
Zach Hornby
Chief Operating Officer
Ignyta
 
About Speaker:

Bin Li
Associate Director, Computational Biology
Takeda
Bin Li
Associate Director, Computational Biology
Takeda
 
About Speaker:

Dr. Bin Li leads a computational biology team at Data Science Institute, Takeda Pharmaceutics. His team provides computational supports on translational medicine research for various Takeda compounds. They also develop methods, build predictive models for biomarker and patient stratification needs, as well as build a cloud-based translational medicine data repository. His team is also responsible on method evaluation and pipeline building for various NGS platforms, including WES, RNA-seq, and targeted NGS panels.


Patricia McLoughlin
Director of Business Development, Personalised Healthcare Molecular Diagnostics
Qiagen
Patricia McLoughlin
Director of Business Development, Personalised Healthcare Molecular Diagnostics
Qiagen
 
About Speaker:

Patricia McLoughlin PhD is Director Precision Diagnostic & Pharma Partnering, Molecular Diagnostics at QIAGEN, where her responsibilities involve establishing and managing partnerships with Pharma clients for the development of Companion Diagnostic assays for approval with their drugs.
Dr McLoughlin started her career as a Research Assistant at The State University of New York before moving to Affymax Research Institute in California as a Research Associate. Dr McLoughlin then moved to F Hoffmann - La Roche Pharmaceuticals in Basel in 2002 where she worked her way through roles of increasing responsibility in the core Genomics and biomarker technology department of Roche, until she was head of Genomics in 2008. During this time she was a key contributor to the establishment of profiling technologies and biomarker sampling in clinical trials across all disease areas in which Roche is active. Her last role at Roche was VP Global Head of Operations, in the Translational Research Sciences department. Most recently Dr McLoughlin worked at Leica Biosystems as Director of Strategic Alliances – Pharma Partnerships where she established relationships with Pharma clients requiring Immunohistochemistry-based CDx assays.
Dr McLoughlin holds a BSc (hons) in Microbiology from the National University of Ireland, Galway, and a Ph.D. in Molecular Biology from the University of Zurich.


James McNamara
Associate Professor, Department of Internal Medicine
University of Iowa
James McNamara
Associate Professor, Department of Internal Medicine
University of Iowa
 
About Speaker:

Dr. McNamara studied Chemical Engineering at the University of Virginia (B.S., 1992), Neurobiology at Duke University (Ph.D., 2003) and then completed a postdoc at Duke where he developed RNA based therapeutic approaches for cancer. He joined the Department of Internal Medicine at the University of Iowa in 2007. Dr. McNamara’s research is focused on developing rapid clinical diagnostic assays for bacterial infectious diseases based on selective detection of pathogen-derived nuclease activities.


Dobrin Nedelkov
Research Scientist, Molecular Biomarkers Laboratory
Biodesign Institute, Arizona State University
Dobrin Nedelkov
Research Scientist, Molecular Biomarkers Laboratory
Biodesign Institute, Arizona State University
 
About Speaker:

Dr. Dobrin Nedelkov is a Scientist and Group Leader of the Molecular Biomarkers Unit in the Biodesign Institute at Arizona State University. He is also a Founding President of the Institute for Population Proteomics.
Dr. Nedelkov received his Ph.D. in Chemistry and Biochemistry from Arizona State University in 1997. After spending a year as a Postdoctoral Associate at Yale University, Dr. Nedelkov joined Intrinsic Bioprobes where over the span of 14 years he progressed through the ranks to ultimately become Scientific Director and CEO of the company, leading the early efforts in technology development for targeted proteomics and protein biomarkers. In 2013 he joined the Biodesign Institute at Arizona State University where he is leading research in proteoform biomarker discovery, validation, and translation.
Dr. Nedelkov has authored over 90 peer reviewed scientific articles, presented at over 60 scientific meetings, has 4 issued patents and several pending patent applications, and has served as a principal investigator on numerous NIH grants.


Alex Parker
Vice President, Biopharma
Foundation Medicine
Alex Parker
Vice President, Biopharma
Foundation Medicine
 
About Speaker:

Dr. Parker has served as the Vice President of Foundation Medicine’s Business Development team since 2014, where he partners with biopharmaceutical companies to bring transformative cancer care to patients. Alex began his journey at Foundation Medicine in 2010 as the company’s Vice President of Process Technology. Prior to joining Foundation Medicine, Dr. Parker was Principal Scientist at Amgen and held various roles at Millennium Pharmaceuticals. He received his Ph.D in Molecular Genetics from the University of Maine and a bachelor’s in Philosophy and Biology from the University of New Mexico.              


Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California San Diego
Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California San Diego
 
About Speaker:

Sandip Patel, MD. Assistant Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center

Dr. Sandip Patel, MD is a medical oncologist focused on early development of novel immunotherapy, in particular early phase clinical trials of cancer immunotherapy and thoracic oncology immunotherapy trials. His research focus is on predictive biomarkers for immunotherapeutic response and generation of personalized cancer immunotherapy regimens.

He is Assistant Director of the Clinical Trials Office at UCSD Moores Cancer Center and a member of the Cancer Immunotherapy, Experimental Therapeutics (Phase 1), and Thoracic Oncology Programs. Dr. Patel earned his medical degree at Baylor College of Medicine, while performing research at MD Anderson Cancer Center. He completed a residency in Internal Medicine at UCLA Medical Center. He completed a fellowship in Medical Oncology and Hematology at Duke University Medical Center. He is triple board-certified in internal medicine, medical oncology, and hematology.


Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
 
About Speaker:

Dr. Anuraag Shrivastav completed his PhD in 2002 from the Banaras Hindu University, India. He received postdoctoral fellowship from Canadian Institutes of Health Research and obtained postdoctoral training at the department of Pathology and Laboratory Medicine and Saskatchewan Cancer Agency, University of Saskatchewan, Canada. Dr Shrivastav is a faculty member at the University of Winnipeg and adjunct member at the University of Manitoba and CancerCare Manitoba. He has published over 40 peer-reviewed articles in International journals of repute. His laboratory is engaged in studying cellular signaling mechanisms that are intricately linked to homeostasis that control cell proliferation, survival and death in cancer cells. Currently, his research group is actively pursuing scientific research to identify novel markers for CRC screening and early detection. Dr. Shrivastav is also Principal, VastCon Inc – A University of Winnipeg spinoff dedicated to developing novel biomarkers based simple prognostic/diagnostic tests.


Steven Skates
Associate Professor, Medicine
Harvard Medical School
Steven Skates
Associate Professor, Medicine
Harvard Medical School
 
About Speaker:

Katherine Tynan
President
Tynan Consulting LLC
Katherine Tynan
President
Tynan Consulting LLC
 
About Speaker:

Dr. Tynan is a seasoned biotechnology entrepreneur with a focus on business development, startup entrepreneurship, fundraising and strategic business planning for clinical diagnostic companies and investors. She has a background in product development, financial analysis, operations, regulatory, evidence development, reimbursement and market access for clinical diagnostics in the US and EU. Currently Katherine works with a number of early stage and established diagnostic companies guiding them through product development choices, market entry strategies, funding across a diversified set of indications and technologies. http://www.tynandx.com/


Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
 
About Speaker:

Xuemei Zhao
Senior Principal Scientist
Merck
Xuemei Zhao
Senior Principal Scientist
Merck
 
About Speaker:

Xuemei Zhao obtained her Ph.D. in Chemistry at Columbia University and did her postdoctoral training at Cold Spring Harbor Laboratory.  Afterwards, Xuemei joined the Proteomics Department at Merck Research Laboratories.  Her group was responsible for biochemical sample preparation for LC-MS based proteomics profiling in biomarker discovery and new target identification.  Xuemei then moved on to focus on clinical biomarker development and implementation.  Currently, Xuemei leads the immunoassay group in Translational Molecular Biomarkers to support clinical programs across all disease areas at Merck.